Medication safety and combined medication in patients with type 2 diabetes mellitus

doi:10.19803/j.1672-8629.2022.03.18

Abstract

Abstract: Objective To investigate the current incidence of adverse drug reactions (ADR) and combined drug regimens for patients with type 2 diabetes mellitus (T2DM). Methods All the ADR reports of T2DM patients in Shaanxi Province collected between 2015 and 2019 were selected to analyze the basic data, clinical manifestations and influencing factors of ADR, and the combined use of drugs. Results A total of 2 050 cases of ADR related to T2DM patients in Shaanxi Province were collected, including damage to the gastrointestinal system, metabolic and nutritional disorders and damage to the skin and its accessories. Femininity, old age and combined drug use were the common causes of ADR, and combined drug use with metformin accounted for the highest proportion of all cases of combined drug use. Conclusion Clinicians should focus their attention on high-risk groups of ADR, including women, elderly patients and users of multiple drug combinations, and select the proper combination of drugs.

Key words: type 2 diabetes mellitus, hypoglycemic drugs, adverse drug reaction, drug combination

CLC Number:

R969.3

XIANG Yufang, SUN Hui, CHEN Yue, WANG Ningsheng, LUO Shishu, ZHANG Zhi, FENG Bianling. Medication safety and combined medication in patients with type 2 diabetes mellitus[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 313-316.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2022.03.18

https://zgywjj.magtechjournal.com/EN/Y2022/V19/I3/313

References

[1] World Health Organization. The top 10 causes of death[EB/OL]. (2020-01-01) [2020-05-01]. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
[2] World Health Organization. Media centre: diabetes[EB/OL]. (2020-02-03) [2020-03-23]. http://www.who.int/en/news-room/fact-sheets/detail/diabetes.
[3] International Diabetes Federation. IDF diabetes atlas 9th edition2019[EB/OL]. (2020-03-01) [2020-04-13].https://diabetesatlas.org/en/.
[4 International Diabetes Federation. Demographic and geographic outline[EB/OL]. (2019-04-11) [2020-04-10]. https://diabetesatlas.org/en/sections/demographic-and-geographic-outline.html.
[5] MORITA Y, MURAYAMA H, ODAWARA M, et al.Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database[J]. Diabetol Metab Syndr, 2019, 11(1): 11-21.
[6] XU Y, WANG L, HE J, et al.Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959.
[7] WANG YZ, CHEN XY, XIAO T, et al.Investigation and analysis of oral drug therapy mode in type 2 diabetes outpatients in big cities of China[J]. Chinese Journal of Disease Control(中华疾病控制杂志), 2018, 22(3): 222-225.
[8] ZHAO H, XU HM, XU JY.Analysis of 1447 cases of adverse reactions to oral anti-diabetes drugs[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2012, 9(12): 737-740.
[9] Chinese guidelines for the prevention and treatment oftype 2 diabetes (2017 edition)[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2018, 38(4): 292-344.
[10] SHAN QM.New advances in the clinical treatment of type 2 diabetes[J]. Medical Equipment(医疗装备), 2019, 32(24): 203-204.
[11] YU YH.A Brief analysis of the action characteristics and mechanism of several oral hypoglycemic drugs[J]. Chinese Medical Guide(中国医药指南), 2014, 12(19): 378-379.
[12] SHI HB, CAI Q.Review of clinical adverse reactions of hypoglycemic agents[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(3): 159-162.
[13] BROŽ J, URBANOVÁ J.A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus[J]. Vnitr Lek, 2019, 65(4):289-294.
[14] TANG L, WANG CC, PENG Y, et al.Research progress of adverse reaction signal detection in combination with drug use[J]. Huaxi Medical Science(华西医学), 2015, 30(3): 585-588.
[15] TANG WL, WANG YM, DU WM, et al.An analysis of adverse reactions of antidiabetic drugs in China for 42 years[J]. Chinese Journal of New Drugs and Clinical Medicine(中国新药与临床杂志), 2002(12): 753-758.

[1]	LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou. Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
[2]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[3]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[4]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[5]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[6]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.
[7]	YANG Xin, YANG Baochun, YANG Yang, SHAO Huan. One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
[8]	WANG Chunting, CHEN Yafei. Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
[9]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[10]	CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
[11]	CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun. Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
[12]	LIN Lu, ZHAO Anzhi, CHEN Jinhui, LI Zhongwen, HUANG Guohua, ZHONG Shilong. One Case of Delayed Hypersensitivity Reactions Caused by Cefotaxime Sodium and Sulbactam Sodium for Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 809-811.
[13]	TANG Jiong, ZENG Yuqi. One Case of Oculomotor Paralysis Caused by Sugemalimab Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 812-814.
[14]	WANG Yuan, LI Ruoning, GUO Zhanli, ZHANG Lei, LI Jiayuan, DONG Ying, SUN Jianjun. One Case of Extremely Severe Thrombocytopenia Caused by Tirofiban Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 815-818.
[15]	LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan. One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.